Investor Presentation H1 2023
25
Investor presentation
First six months of 2023
Novo Nordisk has leading positions in diabetes, obesity and
haemophilia
Diabetes care
DKK
billion
1200
1000
800
Obesity care
DKK
billion
#1
50%
50
40%
40
40
30%
30
Haemophilia
DKK
billion
100%
#1
100
80%
80
60%
60
Novo NordiskⓇ
#3
50%
40%
30%
600
20%
20
20
40%
40
40
20%
400
CAGR¹ value: 16.1%
10%
10
CAGR² value: 108.9%
20%
20
200
20
10%
CAGR³ value: 5.9%
0
May
2018
0%
0
May
2023
May
2021
Market value
0%
0
May
2023
FY
2019
Market value
0%
FY
2022
Market value
NN value market share (RHS)
Global market position
NN value market share (RHS)
Global market position
-NN value market share (RHS)
Global market position
1 CAGR for 5-year period; 2 CAGR for 2-year period; 3 CAGR for 3-year period; RHS: Right-hand side; Note: Annual sales figures for haemophilia A, B and bypassing agent segments, plasma derived products excluded except FeibaⓇ;
Source: Company reports for haemophilia market; IQVIA MAT, May 2023; Note: Diabetes and Obesity care market values are based on list prices in the US.
NN: Novo Nordisk.View entire presentation